The U.S. Congressional Budget Office states that cuts in research funding will lead to a sharp decline in the number of new drugs in the United States over the next 30 years.

Jin10 data reported on July 21 that the U.S. Congressional Budget Office recently stated that the Trump administration plans to significantly cut the budget of the National Institutes of Health (NIH) for 2026, which will ultimately lead to a reduction in the number of drugs on the market, and this impact may manifest over a longer period. The Trump administration previously announced a substantial cut of $18 billion to the 2026 NIH budget, a reduction of 40%. If the budget is passed by the U.S. Congress, it will officially take effect on October 1 of this year. Scientists have also warned that the funding cuts could lead to a large-scale “brain drain.” “The uncertainty of funding will force young researchers to move overseas and undermine the U.S.'s leadership position in global research,” said a researcher from an American university.